BR9712970A - Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica - Google Patents

Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica

Info

Publication number
BR9712970A
BR9712970A BR9712970-4A BR9712970A BR9712970A BR 9712970 A BR9712970 A BR 9712970A BR 9712970 A BR9712970 A BR 9712970A BR 9712970 A BR9712970 A BR 9712970A
Authority
BR
Brazil
Prior art keywords
respiratory syncytial
syncytial virus
protein
fusion protein
mixture
Prior art date
Application number
BR9712970-4A
Other languages
English (en)
Inventor
George A Cates
Sonia E Sanhueza
Raymond P Oomen
Michel H Klein
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24725423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9712970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of BR9712970A publication Critical patent/BR9712970A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

<B>PREPARAçãO DE VACINA DE VìRUS SINCICIAL RESPIRATóRIO DE SUBUNIDADE<D> Proteína de fusão (F), proteína acoplada (G) e a proteína matriz (M) de vírus sincitial respiratório (RSV) são isolados e purificados do vírus sincitial respiratório por extração com detergente brando das proteínas de vírus concentrados, carregados de proteína sobre um hidroxiapatide ou outro coluna matriz de troca iónica e extraindo a proteína utilizando um tratamento salino brando. As proteínas F, G, e M, formuladas como composições imunogênicas, são seguras, e altamente imunogênias, e protegem de forma relevante animais contra doenças causadas por infecção por vírus sincitial respiratório.
BR9712970-4A 1996-07-12 1997-07-11 Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica BR9712970A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/679,060 US6020182A (en) 1996-07-12 1996-07-12 Subunit respiratory syncytial virus vaccine preparation
PCT/CA1997/000497 WO1998002457A1 (en) 1996-07-12 1997-07-11 Subunit respiratory syncytial virus vaccine preparation

Publications (1)

Publication Number Publication Date
BR9712970A true BR9712970A (pt) 2001-08-28

Family

ID=24725423

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712970-4A BR9712970A (pt) 1996-07-12 1997-07-11 Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica

Country Status (15)

Country Link
US (2) US6020182A (pt)
EP (2) EP1477494A1 (pt)
JP (1) JP2000501418A (pt)
CN (1) CN1145639C (pt)
AT (1) ATE282633T1 (pt)
AU (1) AU716378B2 (pt)
BR (1) BR9712970A (pt)
CA (1) CA2259594C (pt)
DE (2) DE942928T1 (pt)
ES (1) ES2141065T5 (pt)
GR (1) GR990300042T1 (pt)
HK (1) HK1022704A1 (pt)
NZ (1) NZ334115A (pt)
RU (1) RU2243234C2 (pt)
WO (1) WO1998002457A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US20020136739A1 (en) * 1996-07-12 2002-09-26 Cates George A. Subunit respiratory syncytial virus preparation
US6017694A (en) * 1997-12-19 2000-01-25 American Cyanamid Company Methods of screening for modulators of respiratory syncytial virus matrix protein interaction
EP1140164B1 (en) * 1998-12-17 2009-02-11 Sanofi Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
WO2001006429A1 (en) * 1999-07-15 2001-01-25 Shea Robert S Method of sequencing chronic disease testing, reporting and evaluation
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
FR2806912B1 (fr) * 2000-04-04 2004-07-23 Fond Mondiale Rech Et Preventi UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
EP1305043A2 (en) * 2000-07-31 2003-05-02 Aventis Pasteur Limited Respiratory syncytial virus vaccine
WO2002012289A2 (en) * 2000-08-07 2002-02-14 Aventis Pasteur Limited Stabilization of immunogens derived from paramyxoviruses
CA2426312C (en) * 2000-10-18 2014-01-14 Ralph A. Tripp Compositions and methods for modulating rsv infection and immunity
KR20040071678A (ko) * 2001-09-28 2004-08-12 유니버시티 오브 사우스 플로리다 Ｒｓｖ 유전자 발현 백신
ES2283614T3 (es) * 2001-12-20 2007-11-01 Sanofi Pasteur Limited Composiciones inmunogenicas que comprenden un antigeno y una proteina m purificada del virus respiratorio sincitial.
WO2003092618A2 (en) 2002-04-30 2003-11-13 University Of South Florida Materials and methods for prevention and treatment of rna viral diseases
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
EP1603940A2 (en) * 2003-03-18 2005-12-14 Wyeth Holdings Corporation Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
CA2703667C (en) * 2007-10-25 2015-12-29 Lawrence M. Kauvar Anti-rsv g protein antibodies
WO2009147248A2 (en) 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
AU2009333484B2 (en) * 2008-12-09 2014-12-11 Novavax, Inc. Modified RSV F proteins and methods of their use
SG176095A1 (en) * 2009-06-05 2011-12-29 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
HRP20220756T1 (hr) * 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
NZ599148A (en) * 2009-10-06 2014-08-29 Medimmune Ltd Rsv-specific binding molecule
MX2012007117A (es) * 2009-12-23 2012-07-23 Sanofi Pasteur Metodo para cultivar celulas adherentes.
CN102199198A (zh) * 2011-03-28 2011-09-28 北京交通大学 人呼吸道合胞病毒f蛋白的纯化方法
JP6523955B2 (ja) 2012-08-01 2019-06-05 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
RU2761631C2 (ru) * 2013-03-13 2021-12-13 Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Белки rsv в предшествующей слиянию конформации и их применение
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
JP6479305B2 (ja) * 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
EP3076999B1 (en) * 2013-12-02 2020-01-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant respiratory syncytial virus g protein fragments
RU2746280C1 (ru) * 2020-08-03 2021-04-12 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Штамм респираторно-синцитиального вируса RSV/Novosibirsk/66Hl/2018 для использования в диагностике респираторно-синцитиальной вирусной инфекции и исследования эффективности противовирусных препаратов in vitro

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01501357A (ja) * 1986-01-14 1989-05-18 ユニバ−シテイ・オブ・ノ−ス・カロライナ ヒト呼吸器系ウイルス用ワクチン
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US5723130A (en) * 1993-05-25 1998-03-03 Hancock; Gerald E. Adjuvants for vaccines against respiratory syncytial virus
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation

Also Published As

Publication number Publication date
CN1145639C (zh) 2004-04-14
AU716378B2 (en) 2000-02-24
NZ334115A (en) 2000-06-23
ES2141065T1 (es) 2000-03-16
EP1477494A1 (en) 2004-11-17
US6020182A (en) 2000-02-01
DE69731659D1 (de) 2004-12-23
AU3431197A (en) 1998-02-09
CA2259594C (en) 2003-11-11
CN1230197A (zh) 1999-09-29
CA2259594A1 (en) 1998-01-22
EP0942928A1 (en) 1999-09-22
HK1022704A1 (en) 2000-08-18
ES2141065T3 (es) 2005-05-01
ES2141065T5 (es) 2009-02-16
DE942928T1 (de) 2000-03-02
US6309649B1 (en) 2001-10-30
EP0942928B2 (en) 2008-08-13
GR990300042T1 (en) 2000-01-31
ATE282633T1 (de) 2004-12-15
EP0942928B1 (en) 2004-11-17
JP2000501418A (ja) 2000-02-08
DE69731659T3 (de) 2009-06-18
WO1998002457A1 (en) 1998-01-22
RU2243234C2 (ru) 2004-12-27
DE69731659T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
BR9712970A (pt) Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica
EP0912743B1 (fr) Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BR9915988A (pt) Vacina para peptidase c5a estreptocócica
WO2000077216A3 (en) Porcine circovirus vaccine in recombinant poxvirus
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
Liu et al. Identification and analysis of a Sciaenops ocellatus ISG15 homologue that is involved in host immune defense against bacterial infection
CA2408328A1 (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
CA2399172A1 (en) Cold-adapted equine influenza viruses
BR9915020A (pt) Sistemas de distribuição de droga originado na mucosa e aplicações animais
DE69940406D1 (de) Ine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält
HK51597A (en) Vaccines for human respiratory virus
PT1015595E (pt) Peptidos derivados da proteina de ligacao (g) do virus sincicial respiratorio
ES2192559T3 (es) Vacuna para la proteccion de aves de corral contra la coccidiosis.
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
DK0682950T3 (da) Slimhindeadministration af pneumokok-antigener
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
TW200505475A (en) Avian E. coli vaccine for protection against colibacillosis
WO2002009749A3 (en) Respiratory syncytial virus vaccine
WO2003022878A3 (en) Subunit respiratory syncytial virus vaccine preparation
EA200200743A1 (ru) Рекомбинантное ослабление вируса репродуктивного и респираторного синдрома свиней (prrsv)
AR009756A1 (es) Composicion farmaceutica para usar en el tratamiento de enfermedades inducidas por el virus sincitial respiratorio
CO5300406A1 (es) Vacuna
BR9814958A (pt) Proteìna de cimento de tecido, composição farmacêutica, uso da proteìna de cimento de tecido, vacina, processos para produção de vacina, para ligação de tecido de animal e para preparação de uma protéina de cimento de tecido, molécula de ácido nucleico, vetor de expressão ou de clonagem, célula hospedeira, e, animal transgênico

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, SUGIRO O INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O, 10 (IX) E 13 DA LPI 9279/96.